Ryan Deschner
Stock Analyst at Jefferies
(4.59)
# 217
Out of 4,876 analysts
12
Total ratings
63.64%
Success rate
43.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INZY Inozyme Pharma | Downgrades: Hold | $15 → $4 | $4.00 | - | 2 | May 16, 2025 | |
| APLS Apellis Pharmaceuticals | Downgrades: Outperform | $75 → $52 | $18.40 | +182.61% | 1 | May 9, 2025 | |
| LQDA Liquidia | Maintains: Strong Buy | $27 → $29 | $12.83 | +126.03% | 3 | May 9, 2025 | |
| TRVI Trevi Therapeutics | Upgrades: Strong Buy | $9 → $29 | $5.66 | +412.37% | 2 | Mar 10, 2025 | |
| ARDX Ardelyx | Reiterates: Strong Buy | $15 → $13 | $3.69 | +252.78% | 1 | Feb 21, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $18.08 | +54.87% | 3 | Jan 14, 2025 |
Inozyme Pharma
May 16, 2025
Downgrades: Hold
Price Target: $15 → $4
Current: $4.00
Upside: -
Apellis Pharmaceuticals
May 9, 2025
Downgrades: Outperform
Price Target: $75 → $52
Current: $18.40
Upside: +182.61%
Liquidia
May 9, 2025
Maintains: Strong Buy
Price Target: $27 → $29
Current: $12.83
Upside: +126.03%
Trevi Therapeutics
Mar 10, 2025
Upgrades: Strong Buy
Price Target: $9 → $29
Current: $5.66
Upside: +412.37%
Ardelyx
Feb 21, 2025
Reiterates: Strong Buy
Price Target: $15 → $13
Current: $3.69
Upside: +252.78%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $18.08
Upside: +54.87%